- Home
- LFST vs MESO Comparison
LFST vs MESO Comparison
Compare LFST & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LFST
- MESO
- Stock Information
- Founded
- LFST 2015
- MESO 2004
- Country
- LFST United States
- MESO Australia
- Employees
- LFST N/A
- MESO N/A
- Industry
- LFST Medical/Nursing Services
- MESO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LFST Health Care
- MESO Health Care
- Exchange
- LFST Nasdaq
- MESO Nasdaq
- Market Cap
- LFST 1.9B
- MESO 2.0B
- IPO Year
- LFST 2021
- MESO N/A
- Fundamental
- Price
- LFST $6.21
- MESO $14.90
- Analyst Decision
- LFST Strong Buy
- MESO Buy
- Analyst Count
- LFST 6
- MESO 2
- Target Price
- LFST $9.00
- MESO $24.00
- AVG Volume (30 Days)
- LFST 2.2M
- MESO 157.6K
- Earning Date
- LFST 11-06-2025
- MESO 08-28-2025
- Dividend Yield
- LFST N/A
- MESO N/A
- EPS Growth
- LFST N/A
- MESO N/A
- EPS
- LFST N/A
- MESO N/A
- Revenue
- LFST $1,367,570,000.00
- MESO $17,198,000.00
- Revenue This Year
- LFST $15.35
- MESO $440.77
- Revenue Next Year
- LFST $14.14
- MESO $110.74
- P/E Ratio
- LFST N/A
- MESO N/A
- Revenue Growth
- LFST 13.39
- MESO 191.39
- 52 Week Low
- LFST $3.74
- MESO $9.61
- 52 Week High
- LFST $8.30
- MESO $22.00
- Technical
- Relative Strength Index (RSI)
- LFST 63.67
- MESO 39.96
- Support Level
- LFST $6.16
- MESO $14.42
- Resistance Level
- LFST $6.44
- MESO $15.61
- Average True Range (ATR)
- LFST 0.31
- MESO 0.47
- MACD
- LFST 0.09
- MESO -0.10
- Stochastic Oscillator
- LFST 78.02
- MESO 27.40
About LFST LifeStance Health Group Inc.
LifeStance Health Group Inc is a mental healthcare company that operates as a provider of outpatient mental health services, spanning psychiatric evaluations and treatment, psychological and neuropsychological testing, and individual, family and group therapy. The group y has a single operating and reportable segment of mental health services.
About MESO Mesoblast Limited
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.